🇺🇸 FDA
Pipeline program

Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Dexamethason 8 mg GALEN® Tabletten, Privigen 100 mg/ml solution for infusion, teclistamab, JNJ-64407564, Pomalidomide, Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Pomalidomide, Imnovid 1 mg hard capsules, Empliciti 400 mg powder for concentrate for solution for infusion., Empliciti 300 mg powder for concentrate for solution for infusion., Pomalidomide, VELCADE 3.5 mg powder for solution for injection, Privigen 100 mg/ml s

64407564MMY3009

Phase 3 small_molecule active

Quick answer

Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Dexamethason 8 mg GALEN® Tabletten, Privigen 100 mg/ml solution for infusion, teclistamab, JNJ-64407564, Pomalidomide, Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Pomalidomide, Imnovid 1 mg hard capsules, Empliciti 400 mg powder for concentrate for solution for infusion., Empliciti 300 mg powder for concentrate for solution for infusion., Pomalidomide, VELCADE 3.5 mg powder for solution for injection, Privigen 100 mg/ml s for Relapsed or Refractory Myeloma is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Relapsed or Refractory Myeloma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials